// App-Quantinova.ai

P2.393 : Tolerability and Retention to Fingolimod in RRMS Patients who Switched from other Oral DMTs (P2.393)

Researchers

Presenter

  • Yves Lapierre

Principal Investigators

  • Mark S. Freedman

  • Francois GrandMaison

  • Liesly Lee

  • Katayoun Alikhani

  • Lorne Kastrukoff

  • Gregg MacLean

  • Paola Haddad

  • Robyn Schecter

Medical Centers

  • Montreal Neurological Institute, Montreal, Quebec, Canada Montreal QC Canada

  • The University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada Ottawa ON Canada

  • University of Calgary Alberta Canada, Calgary, AB, Canada

  • Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada Toronto ON Canada

  • St. John Regional Hospital, Saint John, New Brunswick, Canada Saint John NB Canada

  • Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada Dorval QC Canada

  • Clinique Neuro Rive-Sud, Greenfield park, Quebec, Canada Greenfield Park QC Canada

  • University of British Columbia, Vancouver, British Columbia, Canada Vancouver BC Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Fingolimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Novartis Pharmaceuticals Canada Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved